New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
11:01 EDTTHRX, ZOLT, SA, TROX, TERHigh option volume stocks: THRX ZOLT SA TROX TER
News For THRX;ZOLT;SA;TROX;TER From The Last 14 Days
Check below for free stories on THRX;ZOLT;SA;TROX;TER the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 26, 2014
20:12 EDTTHRXTheravance looks overvalued, Barron's says
Subscribe for More Information
July 25, 2014
17:08 EDTSASeabridge Gold files to sell C$100M of common shares
Subscribe for More Information
09:13 EDTTERTeradyne shares should be bought on pullbacks, says Pacific Crest
Pacific Crest identifies Teradyne as a top pick and recommends looking for opportunities to buy the shares at a discount heading into the seasonally softer 2H14. The firm thinks the company is gaining share and it expects the company to benefit from growth in its semi test and wireless test markets. The firm keeps a $22 price target and Outperform rating on the shares.
July 24, 2014
10:03 EDTTHRXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:32 EDTTHRXTheravance downgraded at BofA/Merrill
Subscribe for More Information
06:07 EDTTHRXTheravance downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
July 23, 2014
18:34 EDTTEROn The Fly: After Hours Movers
UP AFTER EARNINGS: Fortinet (FTNT), up 7.8%... Hanesbrands (HBI), up 5.4%... 8x8 (EGHT), up 5.1%... Infinera (INFN), up 4.9%... Facebook (FB), reverses and is now trading up 5.1% following second quarter earnings conference call. NOTABLE: Twitter (TWTR), up 1.7%, LinkedIn (LNKD), up marginally, and Yelp (YELP), up 1.6% after Facebook reports second quarter results. ALSO HIGHER: Spectranetics (SPNC), up 7.1% after receiving FDA clearance for atherectomy products, Turbo-Tandem and Turbo Elite... Ariad Pharmaceuticals (ARIA), up 7.1%... Jamba (JMBA), up 3.8% after Engaged Capital reports stake in the company and announced that they had discussions with management. DOWN AFTER EARNINGS: AT&T (T), down 1.2%... Angie's List (ANGI), down 16.4%... Tripadvisor (TRIP), down 11.5%... Orchids Paper (TIS), down 7.4%... Cirrus Logic (CRUS), down 6.6%... Cliffs Natural (CLF), down 1.2%... Teradyne (TER), down 4%. ALSO LOWER: Kandi Technologies (KNDI), down 3.8% after being mentioned negatively in a Seeking Alpha blog post.
17:07 EDTTERTeradyne sees Q3 adjusted EPS 34c-43c, consensus 49c
Subscribe for More Information
17:06 EDTTERTeradyne reports Q2 adjusted EPS 54c, consensus 42c
Subscribe for More Information
July 16, 2014
08:03 EDTTROXTronox announces labor agreement with South African unions
Subscribe for More Information
05:38 EDTTHRXGSK, Theravance initiate Phase III IMPACT study
GlaxoSmithKline (GSK) and Theravance (THRX) announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease, or COPD. IMPACT is the first pivotal phase III study in a programme to evaluate a once-daily closed triple combination treatment of an inhaled corticosteroid, or ICS; a long-acting muscarinic antagonist, or LAMA; and a long-acting beta2-adrenergic agonist, or LABA, in patients with COPD. The IMPACT study will enrol approximately 10,000 patients and assess whether the combination of FF, or fluticasone furoate, an ICS, UMEC, or umeclidinium, a LAMA, and VI, or vilanterol, a LABA, all delivered in GSK's Ellipta inhaler, can reduce the annual rate of moderate and severe exacerbations compared with two approved once daily COPD treatments, Relvar/Breo Ellipta, FF/VI, which is an ICS/LABA combination, and Anoro Ellipta, UMEC/VI, which is a LAMA/LABA combination.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use